KIR3DL2 as an Anti-cancer target

Targeting KIR3DL2 with specific antibodies addresses the limitations of current leukemia treatments by reducing leukemia burden and improving survival with minimal side effects.

WO2025245386A1PCT designated stage Publication Date: 2025-11-27LA JOLLA INST FOR IMMUNOLOGY
View PDF 2 Cites -1 Cited by

Patent Information

Application Number
PCT/US2025/030661
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-23
Filing Date
2025-05-22
Publication Date
2025-11-27

Smart Images

  • Figure US2025030661_27112025_PF_FP_ABST
    Figure US2025030661_27112025_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are methods for treating cancer in a subject in need thereof comprising administering an effective amount of an agent that binds to and / or modulates the expression or activity of Killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) to the subject, thereby treating cancer in the subject.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • KIR3DL2 binding agents

    US20240124579A1

  • Humanized antibodies with increased stability

    WO2015136052A1